An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.102 个研究点分布在 7 个国家目标入组 1,120 人开始时间: 2004年10月1日最近更新: 2021年1月27日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 1,120
试验地点: 102
主要终点: To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing percentage of subjects who reach target BP and LDL-C targets as defined by their governing guidelines.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines

排除标准

•High liver enzymes

结局指标

主要结局

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing percentage of subjects who reach target BP and LDL-C targets as defined by their governing guidelines.

次要结局

To asses changes since baseline of lab parameters, BP, safety of titration of amlodipine.atorvastatin to reach targets, to validate Expectations and Satisfaction with Treatment questionnaires.

研究者

发起方

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

申办方类型

Industry

研究点 (102)

Loading locations...

相似试验

已完成

3 期

Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and DyslipidaemiaDyslipidemiaHypertension

NCT00330785Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,250

已完成

4 期

Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And DyslipidemiaHypertensionHyperlipidemia

NCT00174330Pfizer's Upjohn has merged with Mylan to form Viatris Inc.330

已完成

3 期

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switchHypertension

NCT01134393Boehringer Ingelheim502

已完成

不适用

The study for the efficacy of amlodipine/atorvastatin combination drug in patients with type 2 diabetes complicated with hypertention and hypercholestrolemia.Type 2 diabetes complicated with hypertention and hypercholestrolemia

JPRN-UMIN000010895Kanazawa Medical University Diabetes and Endocrinology240

已完成

3 期

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II HypertensionHypertension

NCT00527514Daiichi Sankyo185